
Dexmedetomidine has evolved as a panacea for various applications/ procedures in the perioperative or critical care settings with multiple promising delivery routes. It is fast emerging as a valuable adjunct to regional anaesthesia and analgesia, where future studies are required to build the evidence for its use in central neuraxial blocks, peripheral nerve blocks or even for local site infiltration. Although Dexmedetomidine has α1/α2 selectivity eight times higher than clonidine, an equipotent dosage of both the drugs in supraclavicular brachial plexus block has not been found in literature. We in this study compare clonidine (1ug/kg) and dexmedetomidine (1ug/kg) as an adjuvant to 0.25% bupivacaine in brachial plexus block and found dexmedetomidine as a safe, superior and far better adjuvant.